BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Federico A, Orditura M, Cotticelli G, DE Sio I, Romano M, Gravina AG, Dallio M, Fabozzi A, Ciardiello F, Loguercio C. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Oncol Lett. 2015;9:1628-1632. [PMID: 25789012 DOI: 10.3892/ol.2015.2960] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Lee SH, Song IH, Noh R, Kang HY, Kim SB, Ko SY, Lee ES, Kim SH, Lee BS, Kim AN, Chae HB, Kim HS, Lee TH, Kang YW, Lee JD, Lee HY. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions. BMC Cancer 2015;15:236. [PMID: 25885683 DOI: 10.1186/s12885-015-1273-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
2 Huang M, Lin Q, Wang H, Chen J, Bai M, Wang L, Zhu K, Jiang Z, Guan S, Li Z, Qian J, Li M, Pang P, Shan H. Survival benefit of chemoembolization plus Iodine125 seed implantation in unresectable hepatitis B-related hepatocellular carcinoma with PVTT: a retrospective matched cohort study. Eur Radiol. 2016;26:3428-3436. [PMID: 26792430 DOI: 10.1007/s00330-015-4198-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
3 Lei XF, Ke Y, Bao TH, Tang HR, Wu XS, Shi ZT, Lin J, Zhang ZX, Gu H, Wang L. Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study. World J Clin Cases 2018; 6(5): 74-83 [PMID: 29774219 DOI: 10.12998/wjcc.v6.i5.74] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
4 Wu X, Luo H, Shi B, Di S, Sun R, Su J, Liu Y, Li H, Jiang H, Li Z. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma. Mol Ther 2019;27:1483-94. [PMID: 31078430 DOI: 10.1016/j.ymthe.2019.04.020] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 12.3] [Reference Citation Analysis]
5 Parsons HM, Chu Q, Karlitz JJ, Stevens JL, Harlan LC. Adoption of Sorafenib for the Treatment of Advanced-Stage Hepatocellular Carcinoma in Oncology Practices in the United States. Liver Cancer 2017;6:216-26. [PMID: 29234628 DOI: 10.1159/000473862] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
6 Thrift AP, Natarajan Y, Liu Y, El-Serag HB. Statin Use After Diagnosis of Hepatocellular Carcinoma Is Associated With Decreased Mortality. Clin Gastroenterol Hepatol 2019;17:2117-2125.e3. [PMID: 30625400 DOI: 10.1016/j.cgh.2018.12.046] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
7 Omar HA, Tolba MF, Hung JH, Al-Tel TH. OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCδ/p53. Front Pharmacol 2016;7:463. [PMID: 27965580 DOI: 10.3389/fphar.2016.00463] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
8 de Castro T, Jochheim LS, Bathon M, Welland S, Scheiner B, Shmanko K, Roessler D, Khaled NB, Jeschke M, Ludwig JM, Marquardt JU, Weinmann A, Pinter M, Lange CM, Vogel A, Saborowski A. Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. Ther Adv Med Oncol 2022;14:175883592210802. [DOI: 10.1177/17588359221080298] [Reference Citation Analysis]
9 Leal CRG, Magalhães C, Barbosa D, Aquino D, Carvalho B, Balbi E, Pacheco L, Perez R, de Tarso Pinto P, Setubal S. Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study. Invest New Drugs 2018;36:911-8. [PMID: 29948358 DOI: 10.1007/s10637-018-0621-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Chen X, Liu L, Pan X. Portal vein tumor thrombus in advanced hepatocellular carcinoma: A case report. Oncol Lett 2015;9:2495-8. [PMID: 26137096 DOI: 10.3892/ol.2015.3115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
11 Zhang X, Xi W, Liu L, Wang L. Improvement in Quality of Life and Activities of Daily Living in Patients with Liver Cirrhosis with the Use of Health Education and Patient Health Empowerment. Med Sci Monit 2019;25:4602-8. [PMID: 31223134 DOI: 10.12659/MSM.914487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Kudo M, Matilla A, Santoro A, Melero I, Gracián AC, Acosta-Rivera M, Choo SP, El-Khoueiry AB, Kuromatsu R, El-Rayes B, Numata K, Itoh Y, Di Costanzo F, Crysler O, Reig M, Shen Y, Neely J, Tschaika M, Wisniewski T, Sangro B. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol 2021;75:600-9. [PMID: 34051329 DOI: 10.1016/j.jhep.2021.04.047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kim B, Kim SS, Cho SW, Cheong JY, Huh J, Kim JK, Lee JH, Ahn HR, Cho HJ. Liver stiffness in magnetic resonance elastography is prognostic for sorafenib-treated advanced hepatocellular carcinoma. Eur Radiol 2021;31:2507-17. [PMID: 33033862 DOI: 10.1007/s00330-020-07357-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Li Y, Wu Q, Yu G, Li L, Zhao X, Huang X, Mei W. Polypyridyl Ruthenium(II) complex-induced mitochondrial membrane potential dissipation activates DNA damage-mediated apoptosis to inhibit liver cancer. European Journal of Medicinal Chemistry 2019;164:282-91. [DOI: 10.1016/j.ejmech.2018.12.041] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
15 Zheng W, Feng Y, Bai Y, Feng Z, Yang X, Dang B, Xiao M, Zhang J, Han S. Proanthocyanidins extracted from grape seeds inhibit the growth of hepatocellular carcinoma cells and induce apoptosis through the MAPK/AKT pathway. Food Bioscience 2022;45:101337. [DOI: 10.1016/j.fbio.2021.101337] [Reference Citation Analysis]
16 Tovoli F, Negrini G, Bolondi L. Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma. Hepat Oncol 2016;3:119-36. [PMID: 30191033 DOI: 10.2217/hep-2015-0006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
17 Hinrichs JB, Shin H, Kaercher D, Hasdemir D, Murray T, Kaireit T, Lutat C, Vogel A, Meyer BC, Wacker FK, Rodt T. Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE. Eur Radiol 2016;26:3447-55. [DOI: 10.1007/s00330-015-4203-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
18 Zhao R, Chang Y, Wang X, Zhang P, Zhang C, Lian P. Pylorus-preserving pancreaticoduodenectomy versus standard pancreaticoduodenectomy in the treatment of duodenal papilla carcinoma. Oncol Lett 2018;15:6368-76. [PMID: 29725396 DOI: 10.3892/ol.2018.8156] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Rawla P, Thandra KC, Vellipuram A, Ali CDM. Efficacy and safety of megestrol in the management of hepatocellular carcinoma: a systematic review of the literature. Contemp Oncol (Pozn) 2018;22:209-14. [PMID: 30783383 DOI: 10.5114/wo.2018.82641] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Pinato DJ, Yen C, Bettinger D, Ramaswami R, Arizumi T, Ward C, Pirisi M, Burlone ME, Thimme R, Kudo M, Sharma R. The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development. Aliment Pharmacol Ther. 2017;45:714-722. [PMID: 28116800 DOI: 10.1111/apt.13904] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]